7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal...

January 7, 2020

Please reload

Featured Posts

MaxCyte Strengthens Leadership Team

September 13, 2006


Gaithersburg, Maryland -– MaxCyte Inc., a clinical stage therapeutic company and pioneer in clinical scale cell loading systems for cellular therapy, including personalized cellular approaches, announces the addition of three seasoned individuals to its leadership team. Arthur Mandell, was elected to MaxCyte's Board of Directors, Judith Hedstrom joined the Executive Team in the new role of Senior Vice President, Corporate and Business Development and Carl June, MD became a member of MaxCyte's distinguished roster of Scientific and Medical Advisors.


"We are delighted that these experienced and accomplished individuals have joined the MaxCyte leadership team. As we go forward, their contributions will help build on the successes we have enjoyed this year and position us well to expand our role in the therapeutic development arena", said Doug Doerfler, President and CEO of MaxCyte Inc. "Art Mandell has a strong track record as a seasoned biopharma industry executive and adds additional strategic perspective at all stages of corporate development. Judy Hedstrom brings substantial experience in clinical product development, commercialization and licensing to our team. Carl June is a world-class leader in the area of immunotherapy who has been working with MaxCyte and will continue to lend important expertise in our pursuit of new applications for cell-based therapeutics," he added.


About Art Mandell


Mr. Mandell joined Prestwick Pharmaceuticals in November 2005 as President and COO and currently serves as Executive Strategic Advisor. Mr. Mandell has also served as a Director of the Company since October 2005. Mr. Mandell has over 25 years of healthcare management experience in both the pharmaceutical and biotechnology sectors, with extensive expertise in business development, strategic planning, product development, and commercialization of products and services. Most recently, Mr. Mandell was President, Chief Executive Officer, and a Director of Cellective Therapeutics, Inc., a Maryland-based monoclonal antibody company which was acquired by MedImmune Inc. in October, 2005. Prior to joining Cellective, Mr. Mandell was President, Chief Executive Officer, and still serves as a Director of Stemron Corporation, a therapeutic stem cell company in Gaithersburg, Maryland. In addition, Mr. Mandell served as Senior Vice President and Chief Business Officer of Human Genome Sciences, Inc. (NASDAQ: HGSI), in Gaithersburg, Maryland. Mr. Mandell serves as a Director for the Maryland High Technology Council and as a Director for the MdBio organization. Mr. Mandell was elected to the Board of Directors of MaxCyte in May, 2006.


About MaxCyte


MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility, which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers: one in Phase I/II clinical trials for treatment of chronic lymphocytic leukemia (CLL) and several preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER. 


For more information, visit http://www.maxcyte.com/


Please reload